ProCE Banner Activity

BCMA-Targeted Bispecific Antibodies: A New Approach for Relapsed/Refractory Multiple Myeloma

Clinical Thought
We’ve heard a great deal about BCMA-targeted CAR T-cell therapy and antibody–drug conjugates for R/R MM. In this commentary, Dr Sagar Lonial discusses how BCMA-targeted bispecific therapies will fit in to the treatment landscape.

Released: April 14, 2022

Expiration: April 13, 2023

Share

Faculty

Sagar Lonial

Sagar Lonial, MD, FACP

Chair and Professor 
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Pfizer, Inc.

Faculty Disclosure

Primary Author

Sagar Lonial, MD, FACP

Chair and Professor 
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Sagar Lonial, MD, has disclosed that he has received funds for research support from Bristol-Myers Squibb, Janssen, Novartis, and Takeda; has received consulting fees from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Novartis, Pfizer, Regeneron, and Takeda; and has served as a board member with stock for TG Therapeutics.